{"abstract": "Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company.", "web_url": "https://dealbook.nytimes.com/2009/01/23/do-pfizer-wyeth-talks-leave-crucell-in-the-cold/", "snippet": "Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company.", "lead_paragraph": "Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Do Pfizer-Wyeth Talks Leave Crucell Out in the Cold?", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2009-01-23T18:11:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/92dc8344-87c8-5895-8d7f-d7d782cded57", "word_count": 183, "uri": "nyt://article/92dc8344-87c8-5895-8d7f-d7d782cded57"}